---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-11-12T22:25:19.760016'
end_time: '2026-11-12T22:40:35.263341'
duration_seconds: 915.5
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: PALB2-Related Cancer Predisposition
  mondo_id: MONDO:0700272
  category: Mendelian
  causal_genes: PALB2
  omim_id: not recorded
  synonyms: PALB2-associated hereditary breast and pancreatic cancer
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    save_artifacts: true
    artifact_max_bytes: 5242880
    artifact_keep_runtime: false
    artifact_extra_extensions: []
    artifact_include_globs: []
    artifact_exclude_globs: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
run_metadata:
  job_id: 00e498da-8bbc-40d9-ac30-35a356551094
citation_count: 32
reference_validation:
  total_references: 35
  verified: 35
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 35
  on_topic: 34
  validator_version: 0.5.1
term_validation:
  total_terms: 31
  verified: 30
  not_found: 0
  obsolete: 0
  unverifiable: 1
  confabulation_rate: 0.0
  labels_checked: 21
  labels_matching: 10
  labels_mismatched: 4
  mislabelled_terms:
  - term_id: MONDO:0700272
    reported_labels:
    - PALB2-Related Cancer Predisposition
    - MONDO ID
    ontology_label: PALB2-related cancer predisposition
  - term_id: HP:0100013
    reported_labels:
    - Triple-negative / ER-negative breast cancer enrichment
    - Male breast cancer
    ontology_label: Neoplasm of the breast
  - term_id: HP:0003221
    reported_labels:
    - Chromosome fragility
    ontology_label: Chromosomal breakage induced by crosslinking agents
  - term_id: CHEBI:83766
    reported_labels:
    - CHEBI chemical entities:** olaparib
    ontology_label: olaparib
  labels_variant: 7
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: PALB2-Related_Cancer_Predisposition-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: PALB2-Related_Cancer_Predisposition-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** PALB2-Related Cancer Predisposition
- **MONDO ID:** MONDO:0700272 (if available)
- **Causal gene(s):** PALB2
- **OMIM:** not recorded
- **Synonyms:** PALB2-associated hereditary breast and pancreatic cancer
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **PALB2-Related Cancer Predisposition** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# PALB2-Related Cancer Predisposition (MONDO:0700272): A Comprehensive Disease Characterization

## Summary

**PALB2-Related Cancer Predisposition** is a Mendelian hereditary cancer syndrome caused by germline loss-of-function (LoF) variants in **PALB2** (*Partner And Localizer of BRCA2*; also known as **FANCN**; HGNC:26144; chromosome 16p12.2; OMIM gene 610355). PALB2 encodes a 1,186-amino-acid scaffold protein that physically bridges BRCA1 to the BRCA2–RAD51 machinery to execute homologous-recombination (HR) repair of DNA double-strand breaks. The disease shows a striking dual inheritance architecture: **monoallelic (heterozygous, autosomal-dominant)** pathogenic variants confer high, age-dependent, incompletely penetrant risk of breast, pancreatic, ovarian, and male breast cancer, whereas **biallelic (homozygous or compound heterozygous, autosomal-recessive)** variants cause **Fanconi anemia subtype N (FANCN)**, a severe pediatric disorder with congenital anomalies, bone-marrow failure, and early embryonal tumors.

The central mechanistic insight is that PALB2 is a high-penetrance breast cancer gene—intermediate between BRCA1/2 and the moderate-penetrance genes (ATM, CHEK2)—whose loss produces **homologous recombination deficiency (HRD)**. Landmark international consortium data (Yang et al., 2020) place the absolute female breast cancer risk at approximately **53% by age 80** (relative risk ≈7.18), with additional elevated risks of ovarian (RR ≈2.91), pancreatic (RR ≈2.37), and male breast cancer (RR ≈7.34). The resulting genomic instability is both a driver of tumorigenesis and a therapeutic vulnerability: PALB2-mutant tumors are synthetically lethal to **PARP inhibitors** and hypersensitive to **platinum agents**, with demonstrated clinical responses in breast, ovarian, and other cancers.

Clinically, PALB2 carriers are managed through intensified surveillance—annual breast MRI as the cornerstone, bilateral risk-reducing mastectomy as an option, and familial-history-triggered pancreatic surveillance—plus HRD-directed systemic therapy in established malignancy. This report synthesizes the molecular biology, epidemiology, clinical phenotype, diagnostics, prognosis, treatment, and prevention of PALB2-related cancer predisposition, drawing on 54 reviewed papers and 10 confirmed findings across the investigation.

---

## Disease Information

**PALB2-Related Cancer Predisposition** (MONDO:0700272) is a hereditary cancer predisposition syndrome. The causal gene is unambiguously **PALB2**. Key identifiers and synonyms:

| Attribute | Value |
|---|---|
| Disease name | PALB2-Related Cancer Predisposition |
| MONDO ID | MONDO:0700272 |
| Causal gene | PALB2 (HGNC:26144) |
| Gene OMIM | 610355 |
| Gene locus | Chromosome 16p12.2 |
| Protein | Partner And Localizer of BRCA2 (1,186 aa) |
| Synonyms | FANCN; PALB2-associated hereditary breast and pancreatic cancer |
| Related recessive disease | Fanconi anemia, complementation group N (FANCN) |
| Category | Mendelian |

The information in this report is derived primarily from **aggregated disease-level resources**—international consortium studies (e.g., CARRIERS/BCAC, the PALB2 Interest Group), curated cohorts, clinical guidelines, and mechanistic/structural studies—rather than individual-patient EHR data. The disease spans a dominant adult cancer-predisposition phenotype (monoallelic) and a recessive pediatric Fanconi anemia phenotype (biallelic).

---

## Etiology

### Disease Causal Factors
The primary cause is **genetic**: germline pathogenic variants in PALB2 that abolish or impair its HR scaffolding function. Most germline PALB2 pathogenic variants are **protein-truncating variants (PTVs)**—frameshift, nonsense, and splice-site—producing loss of function. Missense variants are frequently classified as variants of uncertain significance (VUS) and require functional assays to adjudicate pathogenicity (F005, F007).

### Genetic Risk Factors
- **Causal variants:** Monoallelic PALB2 LoF variants confer high breast/pancreatic cancer risk. In the CARRIERS/BCAC panel study of 60,466 cases and 53,461 controls, PTVs in PALB2 were among only five genes with strong breast-cancer association (Dorling et al., [PMID: 33471991](https://pubmed.ncbi.nlm.nih.gov/33471991/)) (F001).
- **Modifier background:** Polygenic risk score (PRS) and family history substantially modify absolute risk; in Yang et al. the lifetime breast cancer risk ranged from ~44% (no family history) to ~76% (strong family history plus adverse polygenic background) (F003).
- **Zygosity as a determinant of phenotype:** One defective allele → dominant cancer predisposition; two defective alleles → recessive Fanconi anemia FANCN (F001, F009).

### Environmental / Lifestyle Risk Factors
No PALB2-specific environmental trigger has been definitively established. General breast/pancreatic cancer risk factors (age, female sex, family history, and—for pancreatic cancer—tobacco smoking) operate on the elevated genetic baseline. Because PALB2-deficient cells cannot efficiently repair DNA crosslinks and double-strand breaks, exposures that induce such damage (ionizing radiation, crosslinking agents) are mechanistically expected to be especially genotoxic in carriers (F002).

### Protective Factors
No validated PALB2-specific genetic protective allele has been identified. Risk-reducing interventions (prophylactic mastectomy, intensified surveillance leading to stage-shift) are the principal means of reducing disease burden (F006).

### Gene–Environment Interactions
The most clearly supported interaction is the **synthetic-lethal relationship between PALB2 loss and DNA-damaging agents** (platinum, PARP inhibitors): the genetic defect converts an otherwise tolerable pharmacologic exposure into a lethal event for the tumor cell (F004). This is a therapeutic gene–drug interaction rather than an environmental disease-causing one.

---

## Phenotypes

### Monoallelic (Autosomal-Dominant) Cancer Phenotype

| Phenotype | HPO term (suggested) | Frequency / risk | Onset | Severity |
|---|---|---|---|---|
| Breast carcinoma (female) | HP:0003002 | ~53% by age 80 (RR ≈7.18) | Adult; enriched in young onset (≤40 y) | Severe; frequently high-grade |
| Triple-negative / ER-negative breast cancer enrichment | HP:0100013 | Enriched (TNBC ~27.5% in PV cohorts) | Adult | Severe |
| Bilateral breast cancer | HP:0003002 | Enriched (35.7% in young PV cohort) | Adult | Severe |
| Ovarian carcinoma | HP:0100615 | RR ≈2.91; absolute ~5% | Adult | Severe |
| Pancreatic carcinoma | HP:0002894 | RR ≈2.37; absolute ~2–3% | Adult | Severe |
| Male breast cancer | HP:0100013 | RR ≈7.34 | Adult | Severe |

Breast tumors in PALB2 carriers are frequently **high-grade** and enriched for **triple-negative/ER-negative** disease, though ER-positive tumors also occur (F005). In a Canadian national cohort of 805 women diagnosed at ≤40 years, 18.6% carried pathogenic variants; PALB2 PVs were found in ~1.2%, and PV frequencies were higher in lobular (29.2%), triple-negative (27.5%), and bilateral (35.7%) tumors (Metcalfe et al., [PMID: 42337046](https://pubmed.ncbi.nlm.nih.gov/42337046/)) (F005).

### Biallelic (Autosomal-Recessive) FANCN Phenotype

| Phenotype | HPO term (suggested) | Notes |
|---|---|---|
| Bone marrow failure | HP:0005528 | Progressive; hallmark of Fanconi anemia |
| Congenital anomalies | HP:0000118 | Variable malformations |
| Medulloblastoma | HP:0002885 | Embryonal brain tumor; genotype-specific |
| Wilms tumor | HP:0002667 | Embryonal renal tumor |
| Neuroblastoma | HP:0003006 | Embryonal tumor |
| Acute leukemia | HP:0001909 | Early-onset |
| Chromosome fragility | HP:0003221 | Hypersensitivity to crosslinkers |

Biallelic PALB2 produces a particularly severe FA form with congenital abnormalities, bone-marrow failure, and very early cancer onset. The FANCN and FANCD1 (BRCA2) groups uniquely develop **embryonal tumors of early onset** (F009).

### Quality of Life Impact
The dominant phenotype imposes substantial psychosocial and functional burden: lifelong cancer anxiety, surveillance regimens, and decisions around risk-reducing surgery. Survey data (FORCE, [PMID: 42894082](https://pubmed.ncbi.nlm.nih.gov/42894082/)) show that women with breast-predisposition variants (including PALB2) report unmet financial needs and significant emotional difficulty preparing for screening results (37.8%), deciding on risk-reducing mastectomy (37.1%), and emotional recovery after surgery (60.2%). The recessive FANCN phenotype causes profound childhood morbidity and early mortality.

---

## Genetic / Molecular Information

### Causal Gene
**PALB2** (HGNC:26144; OMIM gene 610355; chr 16p12.2). Encodes a 1,186-aa protein.

### Protein Domain Architecture (F007)
PALB2 has a modular architecture that explains its scaffolding role:

```
N-terminus ----[Coiled-coil]----[ChAM]----[MRG15-binding]----[WD40 β-propeller]---- C-terminus
                     |                                              |
            homodimerization,                           binds BRCA2, RAD51,
            binds BRCA1 CC                                    RAD51C
```

- **N-terminal coiled-coil (CC) domain:** Mediates PALB2 homodimerization and heterodimeric binding to the BRCA1 coiled-coil. Solution NMR shows the CC domain forms an antiparallel homodimer, and the structural impact of CC missense variants correlates with their HR efficiency (Reddy et al., [PMID: 39745016](https://pubmed.ncbi.nlm.nih.gov/39745016/)) (F007). *"PALB2 forms homodimers via its coiled-coil domain, and during HR, it forms a heterodimeric complex with BRCA1 using the same domain."*
- **C-terminal WD40 7-bladed β-propeller:** Binds BRCA2, RAD51, and RAD51C.
- **Central ChAM (chromatin-association motif) and MRG15-binding region:** Localize PALB2 to chromatin.

Missense variants disrupting the BRCA1–PALB2 interface cause loss of HR and are linked to tumorigenesis; most remain VUS and are reclassified using homodimerization/heterodimerization and HR complementation assays (e.g., mouse embryonic stem cell assays) (F007). An *in vitro* assay for the PALB2–BRCA1 heterodimer recapitulates the effect of known deleterious mutations and reveals that BRCA1 proline substitutions disrupt α-helix formation (Baker et al., [PMID: 39673470](https://pubmed.ncbi.nlm.nih.gov/39673470/)).

### Pathogenic Variants
- **HGNC ID:** HGNC:26144.
- **Classification:** Per ACMG/AMP, most pathogenic/likely-pathogenic PALB2 variants are protein-truncating (PTVs); missense variants are commonly VUS pending functional evidence.
- **Variant type/class:** Predominantly frameshift, nonsense, and splice-site (LoF); missense and structural variants also occur.
- **Somatic vs germline:** Disease predisposition is **germline**; somatic PALB2 alterations and biallelic inactivation occur in tumors (e.g., biallelic BRCA1/BRCA2/PALB2 inactivation observed in ~19.6% of breast cancer brain metastases, [PMID: 42727421](https://pubmed.ncbi.nlm.nih.gov/42727421/)).
- **Functional consequence:** Loss of function (the gene acts as a tumor suppressor; HR-mediator loss).

### Population-Specific / Founder Variants (F010)
PALB2 shows recurrent/founder alleles across populations:

| Population | Variant / finding | Source |
|---|---|---|
| Argentine HBOC | c.1653T>A recurring in 5 unrelated families; PALB2 P/LPV 4.59% (most prevalent non-BRCA) | [PMID: 42011088](https://pubmed.ncbi.nlm.nih.gov/42011088/) |
| Finnish | c.1592delT founder allele | Established in literature |
| Tatar/Bashkir | Single PALB2 PV instances | [PMID: 40419811](https://pubmed.ncbi.nlm.nih.gov/40419811/) |
| Southern Italian | Population-specific LoF variants | [PMID: 39590369](https://pubmed.ncbi.nlm.nih.gov/39590369/) |
| Brazilian (Ceará) | Recurrent germline PVs | [PMID: 35957908](https://pubmed.ncbi.nlm.nih.gov/35957908/) |

### Modifier Genes & Epigenetics
Breast cancer risk in PALB2 carriers is modified by polygenic background (PRS) and family history (F003). No PALB2-specific disease-driving epigenetic signature has been established in germline carriers; tumor-level HRD arises from loss of HR function rather than from a defined methylation program.

### Chromosomal Abnormalities
At the germline level, PALB2 predisposition is caused by point/indel variants rather than large chromosomal rearrangements. At the cellular/tumor level, PALB2 deficiency produces **chromosome fragility, radial chromosome formation, and broad genomic instability** (high genomic instability scores; F004).

---

## Environmental Information
No specific environmental toxin, infectious agent, or occupational exposure is an established cause of PALB2-related predisposition. The disease is fundamentally genetic. Lifestyle factors relevant to the associated cancers (e.g., smoking for pancreatic cancer) modulate risk on the genetic background but are not disease-specific. There is **no infectious etiology**.

---

## Mechanism / Pathophysiology

### Ordered Causal Chain

**Monoallelic (dominant cancer) branch:**
1. A germline heterozygous LoF variant in PALB2 **leads to** one non-functional allele in every cell (carrier state).
2. A somatic "second hit" (loss of heterozygosity or second mutation) in a susceptible cell **results in** biallelic PALB2 inactivation in that clone.
3. Loss of PALB2 **disrupts** the BRCA1→PALB2→BRCA2–RAD51 bridge, **impairing** recruitment of BRCA2 and RAD51 recombinase to DNA double-strand breaks (F002).
4. Impaired HR **leads to** error-prone repair (NHEJ/MMEJ dominance), **producing** homologous recombination deficiency and progressive genomic instability (chromosome fragility, high genomic instability score) (F004).
5. Accumulating mutations and chromosomal aberrations **drive** malignant transformation—preferentially in breast epithelium, and also in ovary, pancreas, and male breast (F003, F005).
6. Clinical manifestation: high-grade, often triple-negative breast carcinoma and other HR-deficient tumors.

**Biallelic (recessive FANCN) branch:**
1. Two defective germline PALB2 alleles **cause** constitutive HR failure in all cells from conception.
2. Global inability to repair DNA interstrand crosslinks **leads to** developmental defects, progressive bone-marrow failure, and chromosome fragility (Fanconi anemia) (F001, F009).
3. In specific tissues this **results in** early embryonal tumors (medulloblastoma, Wilms tumor, neuroblastoma) and acute leukemias (F009).
   - *Inferred step:* the embryonal tumor tropism shared with FANCD1 (BRCA2) suggests a common BRCA2-pathway requirement in neural/renal progenitor genome maintenance.

### Molecular Pathways, Cellular Processes, Protein Dysfunction
- **Pathway:** Homologous recombination DNA double-strand break repair (Reactome R-HSA-5693567; GO:0000724 double-strand break repair via homologous recombination). PALB2 also participates in S/G2 DNA damage checkpoints and protection of transcriptionally active genes (F002). PALB2 and 53BP1 govern post-resection HR (Deng et al., [PMID: 40749686](https://pubmed.ncbi.nlm.nih.gov/40749686/)). *"PALB2 is a mediator of BRCA2-RAD51 DNA break localization; it can also bind BRCA1 or form homodimers with DNA-binding activity via its coiled-coil (CC) domain."*
- **Cellular processes:** Cell-cycle checkpoint control, maintenance of genome stability, apoptosis of irreparably damaged cells. PALB2-deficient cells are hypersensitive to ionizing radiation and interstrand-crosslinking agents (mitomycin C, cisplatin) (F002).
- **Protein dysfunction:** Loss of function via truncation or domain-disrupting missense; failure of the scaffold to assemble the BRCA1–BRCA2–RAD51 complex (F002, F007). *"PALB2 is required for HR by mediating the recruitment of BRCA2 and the RAD51 recombinase to sites of DNA damage."*

### Suggested Ontology Terms
- **GO biological process:** GO:0000724 (double-strand break repair via homologous recombination); GO:0006281 (DNA repair); GO:0006974 (DNA damage response); GO:0000077 (DNA damage checkpoint signaling).
- **GO cellular component:** GO:0005634 (nucleus); GO:0000785 (chromatin); site of DNA double-strand break.
- **CL cell types:** CL:0000066 (epithelial cell); mammary luminal/basal epithelial cells; pancreatic ductal epithelial cell; CL:0000037 (hematopoietic stem cell, for FANCN marrow failure).
- **CHEBI chemical entities:** olaparib (CHEBI:83766), cisplatin (CHEBI:27899), carboplatin (CHEBI:31355).

### Molecular Profiling / Immune Landscape
Rare germline PTVs in DNA-damage-repair genes including PALB2 shape the tumor immune microenvironment: PALB2 (with BRCA1, BRCA2, RAD51D, MSH6) was associated with 1.3- to 2-fold abundance of CD163-positive (M2-like) tumor-associated macrophages across 7,969 invasive breast tumors ([PMID: 42104457](https://pubmed.ncbi.nlm.nih.gov/42104457/)). PALB2-mutant tumors display high genomic instability scores (median GIS 64, IQR 58–74), comparable to BRCA-mutant HRD, across >2,000 ovarian cancers in olaparib trials (F004).

---

## Anatomical Structures Affected

### Organ Level
- **Primary organs (monoallelic):** Breast (UBERON:0000310), ovary (UBERON:0000992), pancreas (UBERON:0001264), male breast.
- **Primary organs/systems (biallelic FANCN):** Bone marrow / hematopoietic system (UBERON:0002371), central nervous system (medulloblastoma), kidney (Wilms tumor), sympathetic nervous system (neuroblastoma).
- **Body systems:** Reproductive, digestive (exocrine pancreas), hematopoietic/immune, nervous.

### Tissue and Cell Level
- **Tissue types:** Glandular epithelium (breast, pancreatic ductal), ovarian surface/fallopian tube epithelium, hematopoietic tissue.
- **Cell populations (suggested CL terms):** Mammary luminal and basal epithelial cells (CL:0002327, CL:0002325), pancreatic ductal cell (CL:0002079), hematopoietic stem cell (CL:0000037), neural progenitor cells (embryonal tumors).

### Subcellular Level
- **Nucleus (GO:0005634)** — site of HR repair and PALB2 chromatin association. PALB2 functions at sites of DNA damage on chromatin via its ChAM and MRG15-binding regions (F007).

### Localization & Lateralization
Breast cancer in PALB2 carriers is frequently **bilateral** (35.7% in a young-onset PV cohort), reflecting the field-wide genetic predisposition (F005).

---

## Temporal Development

### Onset
- **Monoallelic:** Adult-onset cancer, with enrichment among young women (≤40 years). Insidious (asymptomatic carrier state until tumor develops) (F003, F005).
- **Biallelic (FANCN):** Congenital anomalies at birth; bone-marrow failure and embryonal tumors in early childhood (F009).

### Progression
- Cancer progression follows standard tumor staging (AJCC) and subtype biology. Prognosis is driven mainly by **stage and subtype at diagnosis** rather than carrier status per se; early detection via surveillance drives stage-shift and improved outcomes (F008).
- FANCN is progressive, with worsening marrow failure and high early cancer mortality.

### Patterns & Critical Periods
- The **asymptomatic carrier interval** is the critical window for surveillance and risk-reducing intervention. Treatment-induced remission is achievable in established cancer, particularly with HRD-directed agents (F004, F008).

---

## Inheritance and Population

### Epidemiology
- PALB2 pathogenic variants account for **~1%** of breast cancers (F005). PALB2 is one of five genes (with BRCA1, BRCA2, ATM, CHEK2) that together account for **~7–10%** of breast cancers: *"Mutations in BRCA 1, BRCA 2, ATM, CHEK2, and PALB2 account for approximately 7-10% of breast cancers"* (Sporn et al., [PMID: 42998405](https://pubmed.ncbi.nlm.nih.gov/42998405/)).
- In a Canadian national cohort of young women (≤40 y), PALB2 PVs were ~1.2% (10/805), following BRCA1 (50), BRCA2 (46), CHEK2 (24), ATM (13) (F005). In unselected young Black women, PALB2 GPVs were ~0.9% ([PMID: 42252839](https://pubmed.ncbi.nlm.nih.gov/42252839/)).

### Genetic Characteristics
- **Inheritance pattern:** Autosomal dominant (cancer predisposition, monoallelic); autosomal recessive (Fanconi anemia FANCN, biallelic) (F001).
- **Penetrance:** Incomplete and age-dependent (~53% breast cancer risk by age 80) (F003).
- **Expressivity:** Variable—modified by family history and polygenic background (44%–76% lifetime breast cancer risk range) (F003).
- **Founder effects:** Multiple population-specific recurrent alleles (Finnish c.1592delT; Argentine c.1653T>A; others) (F010).
- **Consanguinity:** Relevant to biallelic FANCN (requires two defective alleles; associated with dual-carrier couples) (F009).
- **Genetic anticipation:** Not applicable (not a repeat-expansion disorder).

### Age-Specific Cancer Risks (Yang et al. 2020, [PMID: 31841383](https://pubmed.ncbi.nlm.nih.gov/31841383/))

| Cancer | Relative risk (95% CI) | Absolute risk to age 80 |
|---|---|---|
| Female breast | 7.18 (5.82–8.85) | ~53% (range ~44–76%) |
| Ovarian | 2.91 (1.40–6.04) | ~5% |
| Pancreatic | 2.37 (1.24–4.50) | ~2–3% |
| Male breast | 7.34 (1.28–42.18) | Elevated |
| Prostate | No significant association | — |
| Colorectal | No significant association | — |

### Population Demographics
PALB2 variants occur across populations worldwide, with documented founder/recurrent alleles in Finnish, Argentine, Tatar/Bashkir, Southern Italian, and Brazilian cohorts (F010). The dominant cancer phenotype predominantly affects women (breast/ovarian), with male breast cancer also elevated.

---

## Diagnostics

### Genetic Testing (primary diagnostic modality)
- **Approach:** Multigene panel testing (NGS) is the standard, typically including BRCA1, BRCA2, PALB2, ATM, CHEK2, and other HR genes. Single-gene PALB2 testing or WES/WGS are alternatives.
- **Variant interpretation:** PTVs are classified pathogenic/likely-pathogenic; missense variants often VUS, resolved by functional HR complementation and dimerization assays (F007).
- **Tumor-first workflows:** In metastatic prostate cancer, a tumour-first strategy identified all high-risk carriers (BRCA2, BRCA1, PALB2) and outperformed family-history referral ([PMID: 42800309](https://pubmed.ncbi.nlm.nih.gov/42800309/)). Mainstream/fast-track germline testing in pancreatic cancer expedites actionable results ([PMID: 42541517](https://pubmed.ncbi.nlm.nih.gov/42541517/)).

### Biomarkers & Omics Diagnostics
- **Genomic instability score (GIS) / HRD testing:** PALB2-mutant tumors show high GIS (median 64), supporting HRD-directed therapy decisions (F004).
- **Liquid biopsy / ctDNA:** Used to detect reversion mutations and emergent resistance in HRR-gene tumors (e.g., PALB2 reversions under PARP inhibition, [PMID: 42849324](https://pubmed.ncbi.nlm.nih.gov/42849324/)).

### Imaging
- Breast MRI and mammography for breast surveillance; MRI/MRCP and endoscopic ultrasound (EUS) for pancreatic surveillance in carriers with family history (F006).

### Pathology
- Breast tumors frequently high-grade and triple-negative/ER-negative enriched (F005). FANCN diagnosis supported by chromosome fragility testing (hypersensitivity to crosslinking agents).

### Clinical Criteria & Differential Diagnosis
- Diagnosis rests on identification of a germline PALB2 pathogenic variant plus clinical/family history. Differential diagnoses include BRCA1/2-related HBOC, ATM/CHEK2 moderate-penetrance syndromes, and—for the recessive phenotype—other Fanconi anemia complementation groups (FANCD1/BRCA2, FANCS/BRCA1) (F001, [PMID: 25472942](https://pubmed.ncbi.nlm.nih.gov/25472942/)).

### Screening / Cascade Testing
Cascade testing of at-risk relatives is central. Universal germline testing is recommended in pancreatic cancer ([PMID: 42933936](https://pubmed.ncbi.nlm.nih.gov/42933936/)).

---

## Outcome / Prognosis

- **Prognostic drivers:** Tumor stage and subtype at diagnosis are the principal determinants; carrier status itself is prognostic/predictive mainly through therapy response (F008).
- **Predictive value for targeted therapy:** PALB2-mutant HR+/HER2− metastatic breast cancers (grouped with BRCA) had significantly shorter PFS on first-line endocrine therapy + CDK4/6 inhibitor than wild-type: *"Median PFS was significantly shorter in BRCA/PALB2m patients (9.9 months [7.6-13.0]) compared to BRCA/PALB2wt (15.4 months [13.9-17.3])"* (adjusted HR 1.61, 95% CI 1.24–2.09, p<0.001; 4,283 patients; Guinel et al., [PMID: 41713165](https://pubmed.ncbi.nlm.nih.gov/41713165/))—supporting prioritization of PARP-inhibitor/platinum strategies (F008).
- **Surveillance improves outcomes:** Pancreatic surveillance programs (CAPS, Dutch, IRFARPC) consistently demonstrate stage-shift toward resectable disease and improved survival (F006, [PMID: 42036279](https://pubmed.ncbi.nlm.nih.gov/42036279/)).
- **FANCN prognosis:** Poor, with early bone-marrow failure and early-onset embryonal tumors/leukemias (F009).
- **Resistance:** HRR reversion mutations (including PALB2 reversions) and emergent PARP1 variants reflect selective pressure to escape PARP synthetic lethality ([PMID: 42849324](https://pubmed.ncbi.nlm.nih.gov/42849324/)).

---

## Treatment

### Targeted Therapy — HRD-Directed (NCIT: PARP Inhibitor Therapy)
PALB2 loss causes HRD, rendering tumors synthetically lethal to PARP inhibition (F004):
- **Olaparib:** In TBCRC 048, olaparib monotherapy produced objective responses in metastatic breast cancer with germline PALB2 mutations (Tung et al., [PMID: 33119476](https://pubmed.ncbi.nlm.nih.gov/33119476/); expansion [PMID: 41604601](https://pubmed.ncbi.nlm.nih.gov/41604601/)). A basket phase II trial found objective responses specifically in the PALB2 cohort (with BAP1, BARD1, BRIP1): *"In the BAP1, BARD1, BRIP1 and PALB2 cohorts, objective responses were detected. Olaparib demonstrated meaningful clinical activity across different cancer types with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2"* ([PMID: 42105598](https://pubmed.ncbi.nlm.nih.gov/42105598/)).
- **Talazoparib:** FDA-relevant PARP inhibitor discussed for genetically-driven breast cancer ([PMID: 42133170](https://pubmed.ncbi.nlm.nih.gov/42133170/)).

### Chemotherapy — Platinum Agents (NCIT: Platinum Compound)
Platinum agents (cisplatin, carboplatin) are effective, consistent with PALB2-deficient cells' hypersensitivity to crosslinkers (F002, F004).

### Immunotherapy Combinations
Case-level evidence of durable response to olaparib plus continued PD-1 blockade in germline PALB2-mutated triple-negative breast cancer with leptomeningeal metastasis (PFS ~40 months; [PMID: 42629735](https://pubmed.ncbi.nlm.nih.gov/42629735/)). Combination trials of olaparib with durvalumab/tremelimumab enroll PALB2-mutant tumors ([PMID: 32778095](https://pubmed.ncbi.nlm.nih.gov/32778095/)).

### Surgery (NCIT: Mastectomy)
Bilateral risk-reducing mastectomy is a recognized option for very high-risk carriers via shared decision-making: *"Prophylactic breast surgery is a major risk-reducing option for women at very high risk of breast cancer, particularly carriers of pathogenic variants in BRCA1, BRCA2, PALB2, or TP53"* ([PMID: 43014839](https://pubmed.ncbi.nlm.nih.gov/43014839/)) (F006). Definitive surgical resection applies to localized breast/pancreatic tumors.

### Personalized Medicine
PALB2 status is actionable at ESCAT I/II levels, guiding genotype-directed therapy (F008). HRD/GIS testing and liquid biopsy inform PARP-inhibitor selection and resistance monitoring.

### Treatment Algorithm (conceptual)
```
Germline PALB2 PV identified
        │
        ├─ Unaffected carrier → surveillance + risk-reducing options (prevention)
        │
        └─ Established cancer
                 ├─ HR+/HER2- MBC: consider PARPi/platinum earlier (shorter PFS on CDK4/6i)
                 ├─ TNBC / HRD+: PARPi (olaparib/talazoparib) ± platinum ± PD-1 blockade
                 └─ Pancreatic/ovarian HRD+: platinum-based ± PARPi maintenance
```

---

## Prevention

### Primary Prevention
- **Risk-reducing mastectomy** for very high-risk carriers (F006, [PMID: 43014839](https://pubmed.ncbi.nlm.nih.gov/43014839/)).
- Risk-reducing salpingo-oophorectomy is **not uniformly recommended** for PALB2 (given only modest ovarian risk) but is considered case-by-case (F006).

### Secondary Prevention (Surveillance)
- **Breast:** Annual breast MRI as the cornerstone plus age-tailored mammography: *"High-penetrance variants (BRCA1/2, TP53, PALB2, PTEN) warrant intensified surveillance, with annual MRI as the cornerstone and mammography tailored by gene and age"* ([PMID: 41386971](https://pubmed.ncbi.nlm.nih.gov/41386971/)) (F006).
- **Pancreatic:** MRI/MRCP and/or EUS offered to PALB2 carriers with a family history of pancreatic cancer through PRECEDE, CAPS, and IRFARPC programs (F006, [PMID: 42976359](https://pubmed.ncbi.nlm.nih.gov/42976359/), [PMID: 42036279](https://pubmed.ncbi.nlm.nih.gov/42036279/)).

### Genetic Counseling & Cascade Testing
Genetic counseling, cascade testing of relatives, and reproductive options (including preimplantation genetic testing, especially for couples at risk of having a child with biallelic FANCN) are central to prevention (F009).

### Risk Stratification
Polygenic risk scores and family history refine individual risk estimates and guide surveillance intensity (F003).

---

## Other Species / Natural Disease and Model Organisms

### Taxonomy & Orthologs
- **Human:** PALB2 (NCBI Gene 79728; NCBI Taxon 9606).
- **Mouse:** *Palb2* ortholog (NCBI Taxon 10090). The gene and its HR function are evolutionarily conserved across mammals.

### Model Organisms
- **Mouse knockout:** *Palb2^(-/-)* mice are **embryonic-lethal at ~E9.5**, with mesoderm differentiation defects and elevated p21, phenocopying *Brca1/Brca2* knockouts; *Palb2^(+/-)* mice are normal and fertile (Rantakari et al., [PMID: 20484223](https://pubmed.ncbi.nlm.nih.gov/20484223/)) (F002). *"Homozygous (HO) Palb2((-/-)) mice present with embryonic lethality and die at E9.5 at the latest."*
- **Conditional/tissue-specific models** are required to study adult tumorigenesis given constitutive-knockout lethality.
- **Cellular/in vitro models:** PALB2-deficient cell lines and mouse embryonic stem cell HR complementation assays are used for variant functional classification (F007).

### Phenotype Recapitulation & Limitations
The embryonic lethality of biallelic *Palb2* loss recapitulates the essential genome-maintenance role but limits modeling of the adult dominant cancer phenotype; conditional and humanized approaches are needed. Naturally occurring PALB2 disease in companion animals is not well documented (data not available). There is no established zoonotic or infectious component.

---

## Mechanistic Model / Interpretation

The unifying model is that **PALB2 is the molecular linchpin of the BRCA1–BRCA2–RAD51 homologous recombination axis**, and its dosage determines a bimodal clinical outcome:

```
                        PALB2 gene
                            │
        ┌───────────────────┴────────────────────┐
   One LoF allele (germline)              Two LoF alleles (germline)
        │                                          │
   Carrier state → somatic 2nd hit            Constitutive HR failure
        │                                          │
   Tissue-restricted biallelic loss         Global genome instability
        │                                          │
   HRD in breast/ovary/pancreas            Fanconi anemia FANCN
        │                                          │
   Adult, high-penetrance cancers        Marrow failure + congenital
   (AUTOSOMAL DOMINANT)                   anomalies + embryonal tumors
        │                                   (AUTOSOMAL RECESSIVE)
        ▼                                          ▼
   PARPi/platinum sensitivity            Severe childhood disease
   (therapeutic vulnerability)           (poor prognosis)
```

Upstream, the initiating lesion is always the PALB2 variant; downstream, the shared mechanistic node is **homologous recombination deficiency**, which both drives tumorigenesis (through genomic instability) and creates the therapeutic Achilles' heel exploited by PARP inhibitors and platinum. PALB2 sits intermediate between BRCA1/2 and the moderate-penetrance genes (ATM, CHEK2) in the hierarchy of breast cancer risk genes, a position justified by its RR ≈7 and ~53% lifetime breast cancer risk.

---

## Evidence Base

| PMID | Study focus | Supports |
|---|---|---|
| [33471991](https://pubmed.ncbi.nlm.nih.gov/33471991/) | Breast cancer risk genes — >113,000 women | PALB2 among 5 strongly associated genes (F001, F005) |
| [31413733](https://pubmed.ncbi.nlm.nih.gov/31413733/) | PALB2 (partner and localizer of BRCA2) review | HR mechanism; biallelic → FA (F001, F002) |
| [34687993](https://pubmed.ncbi.nlm.nih.gov/34687993/) | FANCD1/FANCN genotype–cancer association | Embryonal tumor spectrum in FANCN (F001, F009) |
| [20484223](https://pubmed.ncbi.nlm.nih.gov/20484223/) | Palb2 inactivation in mice | Embryonic lethality; essential HR role (F002) |
| [31841383](https://pubmed.ncbi.nlm.nih.gov/31841383/) | Cancer risks with germline PALB2 (Yang 2020) | Age-specific risk estimates (F003) |
| [42105598](https://pubmed.ncbi.nlm.nih.gov/42105598/) | Olaparib basket trial (BAP1/BARD1/BRIP1/PALB2) | PARPi efficacy in PALB2 (F004) |
| [39695768](https://pubmed.ncbi.nlm.nih.gov/39695768/) | Genomic instability in >2000 ovarian cancers | High GIS in PALB2 tumors (F004) |
| [33119476](https://pubmed.ncbi.nlm.nih.gov/33119476/) / [41604601](https://pubmed.ncbi.nlm.nih.gov/41604601/) | TBCRC 048 | Olaparib responses in gPALB2 MBC (F004) |
| [42337046](https://pubmed.ncbi.nlm.nih.gov/42337046/) | Young women breast cancer cohort | PALB2 ~1.2%; TNBC/bilateral enrichment (F005) |
| [42998405](https://pubmed.ncbi.nlm.nih.gov/42998405/) | Breast cancer gene mutation carriers | PALB2 among 7–10% PAF genes (F005) |
| [41386971](https://pubmed.ncbi.nlm.nih.gov/41386971/) | Imaging surveillance guide | Annual MRI for PALB2 (F006) |
| [43014839](https://pubmed.ncbi.nlm.nih.gov/43014839/) | Prophylactic mastectomy indications | Risk-reducing surgery for PALB2 (F006) |
| [39745016](https://pubmed.ncbi.nlm.nih.gov/39745016/) | PALB2 coiled-coil structural analysis | Domain architecture (F007) |
| [39673470](https://pubmed.ncbi.nlm.nih.gov/39673470/) | BRCA1 coiled-coil proline variants | PALB2–BRCA1 interface (F007) |
| [40749686](https://pubmed.ncbi.nlm.nih.gov/40749686/) | PALB2 and 53BP1 in HR | Mediator role; post-resection HR (F007) |
| [41713165](https://pubmed.ncbi.nlm.nih.gov/41713165/) | BRCA/PALB2 and CDK4/6i efficacy | Predictive value, shorter PFS (F008) |
| [42011088](https://pubmed.ncbi.nlm.nih.gov/42011088/) | Argentine HBOC cohort | Founder variant c.1653T>A (F010) |

---

## Limitations and Knowledge Gaps

1. **Missense VUS burden:** A large fraction of PALB2 missense variants remain variants of uncertain significance; functional assays are not yet comprehensive, limiting clinical actionability for many carriers (F007).
2. **Ovarian/pancreatic risk precision:** Absolute ovarian (~5%) and pancreatic (~2–3%) risk estimates have wide confidence intervals; optimal surveillance thresholds and the net benefit/harm of pancreatic screening (overdiagnosis risk) remain uncertain (F003, F006).
3. **Variant-specific risk modifiers:** How specific variant position/domain and polygenic background interact to set individual penetrance is incompletely quantified.
4. **Model limitations:** Constitutive *Palb2* knockout is embryonic-lethal, so adult tumorigenesis requires conditional/humanized models that only partially recapitulate human disease (F002).
5. **Resistance mechanisms:** PALB2 reversion mutations and PARP1 alterations drive acquired PARPi resistance; strategies to overcome or forestall resistance are underdeveloped.
6. **Underrepresented populations:** Most risk estimates derive from European-ancestry cohorts; population-specific founder alleles (Argentine, Finnish, Tatar/Bashkir, Italian, Brazilian) indicate a need for broader ancestral data (F010).

## Proposed Follow-up Experiments / Actions

1. **Scale functional variant classification:** Deploy high-throughput saturation genome editing / HR complementation assays across all PALB2 domains to reclassify VUS, prioritizing the WD40 and coiled-coil interfaces (builds on F007).
2. **Prospective pancreatic surveillance outcomes:** Analyze PRECEDE/CAPS/IRFARPC longitudinal data specifically for PALB2 carriers to quantify stage-shift and survival benefit and refine eligibility (builds on F006).
3. **Define ovarian risk-management policy:** Conduct a dedicated PALB2 ovarian-risk cohort study to determine whether/when risk-reducing salpingo-oophorectomy is justified.
4. **Earlier HRD-directed therapy trials:** Given shorter PFS on CDK4/6 inhibitors in BRCA/PALB2 HR+/HER2− MBC, design trials sequencing PARP inhibitors/platinum earlier in PALB2 carriers (builds on F008).
5. **Resistance monitoring and combinations:** Use serial ctDNA to detect PALB2 reversions and test PARPi + immunotherapy or ATR-inhibitor combinations to delay resistance.
6. **Ancestry-diverse risk estimation:** Expand consortium analyses to non-European populations and catalog founder alleles to improve equitable risk stratification (builds on F010).
7. **Conditional/humanized mouse models:** Develop tissue-specific and humanized-allele Palb2 models to study adult mammary/pancreatic tumorigenesis and preclinical therapy response.

---

*Report compiled from 10 confirmed findings and 54 reviewed papers. Evidence source types span human clinical consortium studies, curated cohorts, in vitro/structural biology, and mouse model-organism data, as indicated per claim.*


## Artifacts

- [OpenScientist final report](PALB2-Related_Cancer_Predisposition-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](PALB2-Related_Cancer_Predisposition-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.5.1.

| Outcome | Count |
| --- | --- |
| References checked | 35 |
| Resolved | 35 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 35 |
| On topic | 34 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 31 |
| Resolved | 30 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 1 |
| Terms whose name was checked | 21 |
| Terms named correctly | 10 |
| Terms named as a **different** term | 4 |
| Terms whose name is worth a second look | 7 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0700272` (3 mentions) - the report calls it "PALB2-Related Cancer Predisposition", "MONDO ID"; MONDO calls it **PALB2-related cancer predisposition**
- `HP:0100013` (2 mentions) - the report calls it "Triple-negative / ER-negative breast cancer enrichment", "Male breast cancer"; HP calls it **Neoplasm of the breast**
- `HP:0003221` (1 mention) - the report calls it "Chromosome fragility"; HP calls it **Chromosomal breakage induced by crosslinking agents**
- `CHEBI:83766` (1 mention) - the report calls it "CHEBI chemical entities:** olaparib"; CHEBI calls it **olaparib**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0003002` (2 mentions) - the report calls it "Breast carcinoma (female)", "Bilateral breast cancer"; HP calls it **Breast carcinoma**, and lists "Breast cancer" among its other names
- `HP:0100615` (1 mention) - the report calls it "Ovarian carcinoma"; HP calls it **Ovarian neoplasm**, and lists "Ovarian cancer" among its other names
- `HP:0002894` (1 mention) - the report calls it "Pancreatic carcinoma"; HP calls it **Neoplasm of the pancreas**, and lists "Pancreatic cancer" among its other names
- `HP:0000118` (1 mention) - the report calls it "Congenital anomalies"; HP calls it **Phenotypic abnormality**, and lists "Organ abnormality" among its other names
- `HP:0002667` (1 mention) - the report calls it "Wilms tumor"; HP calls it **Nephroblastoma**, and lists "Wilms tumor" among its other names
- `HP:0001909` (1 mention) - the report calls it "Acute leukemia"; HP calls it **Leukemia**
- `CL:0000037` (2 mentions) - the report calls it "hematopoietic stem cell, for FANCN marrow failure"; CL calls it **hematopoietic stem cell**

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `MONDO:0700272` - called "PALB2-Related Cancer Predisposition", "MONDO ID"
- `HP:0003002` - called "Breast carcinoma (female)", "Bilateral breast cancer"
- `HP:0100013` - called "Triple-negative / ER-negative breast cancer enrichment", "Male breast cancer"
- `GO:0005634` - called "nucleus", "Nucleus"